A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol
Open Access
- 14 August 2009
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 24 (12), 3063-3072
- https://doi.org/10.1093/humrep/dep291
Abstract
Corifollitropin alfa, a fusion protein lacking LH activity, has a longer elimination half-life and extended time to peak levels than recombinant FSH (rFSH). A single injection of corifollitropin alfa may replace seven daily gonadotrophin injections during the first week of ovarian stimulation. In this large, double-blind, randomized, non-inferiority trial the ongoing pregnancy rates were assessed after one injection of 150 µg corifollitropin alfa during the first week of stimulation and compared with daily injections of 200 IU rFSH using a standard GnRH antagonist protocol. The study population comprised 1506 treated patients with mean age of 31.5 years and body weight of 68.6 kg. Ongoing pregnancy rates of 38.9% for the corifollitropin alfa group and 38.1% for rFSH were achieved, with an estimated non-significant difference of 0.9% [95% confidence interval (CI): −3.9; 5.7] in favor of corifollitropin alfa. Stratified analyses of pregnancy rates confirmed robustness of this primary outcome by showing similar results regardless of IVF or ICSI, or number of embryos transferred. A slightly higher follicular response with corifollitropin alfa resulted in a higher number of cumulus–oocyte-complexes compared with rFSH [estimated difference 1.2 (95% CI: 0.5; 1.9)], whereas median duration of stimulation was equal (9 days) and incidence of (moderate/severe) ovarian hyperstimulation syndrome was the same (4.1 and 2.7%, respectively P = 0.15). Corifollitropin alfa is a novel and effective treatment option for potential normal responder patients undergoing ovarian stimulation with GnRH antagonist co-treatment for IVF resulting in a high ongoing pregnancy rate, equal to that achieved with daily rFSH. The trial was registered under ClinicalTrials.gov identifier NTC00696800.Keywords
This publication has 39 references indexed in Scilit:
- Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequencyHuman Reproduction Update, 2009
- Update on the comparison of assisted reproduction outcomes between Europe and the USA: the 2002 dataFertility and Sterility, 2007
- Psychological impact of infertilityBest Practice & Research Clinical Obstetrics & Gynaecology, 2007
- A formal comparison of the practice of assisted reproductive technologies between Europe and the USAHuman Reproduction, 2006
- GnRH antagonists in ovarian stimulation for IVFHuman Reproduction Update, 2006
- Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cyclesFertility and Sterility, 2006
- Reasons for discontinuation of IVF treatment: a questionnaire studyHuman Reproduction, 2005
- Why do couples discontinue in vitro fertilization treatment? a cohort studyFertility and Sterility, 2004
- Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacyHuman Reproduction Update, 1996
- Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptidesEndocrinology, 1992